Related Experiment Videos
Antihypertensive therapy: new strategies beyond blood pressure control
1Medizinische Universitäts-Poliklinik, Bonn, Germany.
Insights
Current hypertension treatments lower blood pressure but don't reduce cardiovascular risk, potentially due to drug side effects and comorbidities. New strategies should address hemodynamics, structure, metabolism, and quality of life for better outcomes.
Area of Science:
- Cardiology
- Pharmacology
- Internal Medicine
Background:
- Essential hypertension is a prevalent condition in Western populations, often managed with pharmacologic therapy.
- While diuretics and beta-blockers reduce cardiovascular morbidity and mortality, they haven't convincingly reduced coronary artery disease incidence.
- Treated hypertensive patients still face elevated cardiovascular risk compared to normotensive individuals.
Purpose of the Study:
- To explore reasons for the limited cardiovascular benefit of current antihypertensive therapies.
- To identify factors influencing optimal first-line antihypertensive choices.
- To propose a new therapeutic approach for hypertension management.
Main Methods:
- Review of clinical trial data on antihypertensive therapy outcomes.
- Analysis of potential negative effects of common antihypertensive drugs on metabolic factors.
- Consideration of comorbidities associated with hypertension and their impact on treatment.
Main Results:
- Current antihypertensive drugs may negatively affect serum lipids, glucose, and insulin resistance.
- Associated conditions like hyperlipidemia, diabetes, and cardiac/vascular diseases complicate treatment decisions.
- Negative impacts on quality-of-life factors can lead to poor treatment compliance.
Conclusions:
- A new therapeutic approach for hypertension should integrate blood pressure lowering with beneficial effects on hemodynamics, vascular and cardiac structure, metabolism, and quality of life.
- Optimal antihypertensive therapy must consider patient comorbidities and drug-specific side effects.
- Addressing these multifaceted aspects is crucial for improving long-term cardiovascular outcomes in hypertensive patients.
Abstract:
Mild-to-moderate essential hypertension is the most common medical problem seen by physicians in Western populations, and pharmacologic antihypertensive therapy is now usually undertaken. Clinical trials have shown that lowering of elevated blood pressure using diuretics and beta-blockers reduces cardiovascular morbidity and mortality. Despite these benefits, the trials have provided no convincing evidence that the incidence of coronary artery disease or its complications is reduced: Treated hypertensive patients remain at increased cardiovascular risk compared with untreated normotensive subjects. Possible explanations for this disappointing outcome are that the drugs used may themselves have negative effects on serum lipids, glucose, and insulin resistance, thereby outweighing their antihypertensive benefits. An equally important role in this respect may be played by the diseases and therapies most commonly found in association with mild-to-moderate hypertension: hyperlipidemia, type II diabetes, coronary artery disease, left ventricular hypertrophy, cardiac arrhythmias, peripheral arterial disease, and nephropathy. Such conditions may be potent determinants of what constitutes the optimal first-line choice of antihypertensive therapy. Furthermore, the negative effects that antihypertensive drugs can have on quality-of-life factors may result in noncompliance and ineffective long-term treatment. Therefore, in a new therapeutic approach to the treatment of high blood pressure, it would be logical to base antihypertensive therapy on strategies that not only lower the blood pressure but that have beneficial impacts on hemodynamics, vascular and cardiac structure, metabolism, and quality-of-life issues.(ABSTRACT TRUNCATED AT 250 WORDS)